251 related articles for article (PubMed ID: 21271310)
21. Do metalloproteinases destabilize vulnerable atherosclerotic plaques?
Newby AC
Curr Opin Lipidol; 2006 Oct; 17(5):556-61. PubMed ID: 16960505
[TBL] [Abstract][Full Text] [Related]
22. Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli.
Rodriguez JA; Orbe J; Martinez de Lizarrondo S; Calvayrac O; Rodriguez C; Martinez-Gonzalez J; Paramo JA
Front Biosci; 2008 Jan; 13():2916-21. PubMed ID: 17981764
[TBL] [Abstract][Full Text] [Related]
23. Matrix metalloproteinases and coronary artery diseases.
Ikeda U; Shimada K
Clin Cardiol; 2003 Feb; 26(2):55-9. PubMed ID: 12625594
[TBL] [Abstract][Full Text] [Related]
24. Inhibiting extracellular matrix metalloproteinase inducer maybe beneficial for diminishing the atherosclerotic plaque instability.
Xie S; Nie R; Wang J
J Postgrad Med; 2009; 55(4):284-6. PubMed ID: 20083879
[TBL] [Abstract][Full Text] [Related]
25. Metalloproteinases promote plaque rupture and myocardial infarction: A persuasive concept waiting for clinical translation.
Newby AC
Matrix Biol; 2015; 44-46():157-66. PubMed ID: 25636537
[TBL] [Abstract][Full Text] [Related]
26. The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture.
Teng N; Maghzal GJ; Talib J; Rashid I; Lau AK; Stocker R
Redox Rep; 2017 Mar; 22(2):51-73. PubMed ID: 27884085
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinases: a potential therapeutic target in atherosclerosis.
Rouis M
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):541-8. PubMed ID: 16503874
[TBL] [Abstract][Full Text] [Related]
28. Targeting of matrix metalloproteinase activation for noninvasive detection of vulnerable atherosclerotic lesions.
Hartung D; Schäfers M; Fujimoto S; Levkau B; Narula N; Kopka K; Virmani R; Reutelingsperger C; Hofstra L; Kolodgie FD; Petrov A; Narula J
Eur J Nucl Med Mol Imaging; 2007 Jun; 34 Suppl 1():S1-8. PubMed ID: 17497106
[TBL] [Abstract][Full Text] [Related]
29. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases.
Siasos G; Tousoulis D; Kioufis S; Oikonomou E; Siasou Z; Limperi M; Papavassiliou AG; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1132-48. PubMed ID: 22519444
[TBL] [Abstract][Full Text] [Related]
31. Metalloproteinases and advanced glycation end products: coupled navigation in atherosclerotic plaque pathophysiology?
Furfaro AL; Sanguineti R; Storace D; Monacelli F; Puzzo A; Pronzato MA; Odetti P; Traverso N
Exp Clin Endocrinol Diabetes; 2012 Nov; 120(10):586-90. PubMed ID: 23073918
[TBL] [Abstract][Full Text] [Related]
32. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
[TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease.
Bench TJ; Jeremias A; Brown DL
Pharmacol Res; 2011 Dec; 64(6):561-6. PubMed ID: 21624471
[TBL] [Abstract][Full Text] [Related]
34. Up-regulation of PCSK6 by lipid oxidation products: A possible role in atherosclerosis.
Testa G; Staurenghi E; Giannelli S; Sottero B; Gargiulo S; Poli G; Gamba P; Leonarduzzi G
Biochimie; 2021 Feb; 181():191-203. PubMed ID: 33359561
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance.
Tayebjee MH; Lip GY; MacFadyen RJ
Curr Med Chem; 2005; 12(8):917-25. PubMed ID: 15853705
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinases in vascular physiology and disease.
Siefert SA; Sarkar R
Vascular; 2012 Aug; 20(4):210-6. PubMed ID: 22896663
[TBL] [Abstract][Full Text] [Related]
37. Metalloproteinases in atherosclerosis.
Johnson JL
Eur J Pharmacol; 2017 Dec; 816():93-106. PubMed ID: 28893577
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinases and vulnerable atheromatous plaque.
Toutouzas K; Synetos A; Nikolaou C; Tsiamis E; Tousoulis D; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1166-80. PubMed ID: 22519447
[TBL] [Abstract][Full Text] [Related]
39. Specific matrix metalloproteinases play different roles in intraplaque angiogenesis and plaque instability in rabbits.
Liu XQ; Mao Y; Wang B; Lu XT; Bai WW; Sun YY; Liu Y; Liu HM; Zhang L; Zhao YX; Zhang Y
PLoS One; 2014; 9(9):e107851. PubMed ID: 25233229
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach.
Lancelot E; Amirbekian V; Brigger I; Raynaud JS; Ballet S; David C; Rousseaux O; Le Greneur S; Port M; Lijnen HR; Bruneval P; Michel JB; Ouimet T; Roques B; Amirbekian S; Hyafil F; Vucic E; Aguinaldo JG; Corot C; Fayad ZA
Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):425-32. PubMed ID: 18258820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
